Claims for Patent: 9,725,716
✉ Email this page to a colleague
Summary for Patent: 9,725,716
Title: | Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease |
Abstract: | Disclosed are compositions comprising an antisense oligonucleotide and a non-ionic, low-osmolar contrast agent. Also disclosed are methods of delivering an antisense oligonucleotide to a target sire comprising incorporating the antisense oligonucleotide into a composition comprising a non-ionic, low-osmolar contrast agent. Also disclosed are methods of treating a neurodegenerative disease comprising administering one or more of the compositions disclosed herein. |
Inventor(s): | Burghes; Arthur (Columbus, OH), Porensky; Paul (Worthington, OH), Kaspar; Brian (New Albany, OH) |
Assignee: | Ohio State Innovation Foundation and Research Institute at Nationwide Children\'s Hospital (Columbus, OH) |
Application Number: | 14/363,670 |
Patent Claims: | 1. A composition comprising an antisense oligonucleotide complexed to a non-ionic, low-osmolar contrast agent.
2. The composition of claim 1, wherein the low-osmolar contrast agent is iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol or ioxilan. 3. The composition of claim 2, wherein the non-ionic, low-osmolar contrast agent is iohexol. 4. The composition of claim 1, wherein the antisense oligonucleotide is a morpholino, siRNA, or shRNA. 5. The composition of claim 4, wherein the antisense oligonucleotide disrupts translation, binds to a target nucleotide, induces exon skipping, blocks an intron splice silencer, blocks an exon splice enhancer, binds to a repeat nucleotide sequence, or blocks binding to a sequence in toxic RNA. 6. The composition of claim 1, wherein the antisense oligonucleotide is a morpholino that binds to a survival motor neuron (SMN) gene, a mutated SOD1 gene, C9orf72 repeats, alpha-synuclein, dystrophia myotonic protein kinase gene (DMPK) repeats, Zinc Finger Protein 9 (ZNF9) repeats, a negative regulatory element in intro 6 or intron 7 of SMN2. 7. The composition of claim 1, wherein the morpholino comprises the sequence set forth in SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7. 8. A method of delivering an antisense oligonucleotide to a tissue, organ, or system in a subject comprising administering to the subject the composition of claim 1. 9. A method of treating a neurological disease in a patient in need thereof comprising administering to the patient the composition of claim 1. 10. The method of claim 9, wherein the neurological disease is selected from the group consisting of Alzheimer's disease, Spinal muscular atrophy (SMA), Myotonic dystrophy, Huntington's disease, Parkinson's disease, Spinocerebellar degeneration, Spinocerebellar ataxia, Friedreich's ataxia, Ataxia telangiectasia, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Vasomotor ataxia, Vestibulocerebellar, Ataxiadynamia, Ataxiophemia, Amyotrophic lateral sclerosis, and Olivopontocerebellar atrophy. |
Details for Patent 9,725,716
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2031-12-06 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2031-12-06 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2031-12-06 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.